EQL Pharma was founded by Karin Wehlin and Christer Fåhræus in Lund, Sweden, in 2006, based on the vision to deliver quality pharmaceuticals to the Nordic and the European markets at affordable prices.
The name EQL, as in equal, was chosen to emphasize the companys belief in providing equivalent products at better prices.
Sweden was the first market that EQL pharma entered and the first product sale was Venlafaxin EQL Pharma, in 2008. The first product sale in Finland was Anastrozol EQL Pharma, in 2009. The first approval in Denmark was Anastrozol EQL Pharma, also in 2009.
In 2010, EQL Pharma became the local distributor for the first product from another originating company, Mometason Glenmark.